Heart Health Genetics

Your risk of heart disease was being set in motion before you took your first breath. The genes you inherited shape how your liver clears cholesterol, how much lipoprotein(a) circulates in your blood, how aggressively plaque builds in your artery walls, and how well some of the most common heart drugs work in your body.

This panel reads the genetic blueprint that sits behind every blood draw you have ever had. It pulls together polygenic risk scores for the major lipid disorders, single-gene variants in the highest-impact heart genes, and pharmacogenetic markers that predict how you respond to statins and blood thinners. You do this once, and the information stays true for the rest of your life.

What This Panel Reveals

The panel tells four overlapping stories about your heart, and each story is told by a different group of markers. Reading them together is the point. No single result settles the question of your cardiovascular risk.

Inherited Cholesterol Handling

The familial hypercholesterolemia genes (LDLR, APOB, and PCSK9) drive the most consequential inherited cholesterol disorders. A single pathogenic variant in any of them causes lifelong LDL cholesterol elevation and meaningfully higher cardiovascular risk than the LDL number alone would suggest. Among adults with clinically diagnosed familial hypercholesterolemia, carrying a confirmed pathogenic variant raises atherosclerotic risk beyond what the cholesterol level predicts.

APOE is the other heavy hitter in this group. Carrying one or two E4 alleles raises LDL cholesterol, particularly on diets high in saturated fat, and is associated with atherosclerosis in multiple vascular beds. The protective E2 allele works in the opposite direction, while E3 sits at the population baseline.

The Polygenic Background

The polygenic risk scores summarize the combined effect of many small variants on hypercholesterolemia, low HDL, triglycerides, combined hyperlipidemias, lipoprotein(a), and the body's cholesterol clearance pathway. Each score is a single number representing tens to hundreds of thousands of DNA variants.

People in the top few percent of a coronary artery disease polygenic score can carry a lifetime heart attack risk similar to that of someone with familial hypercholesterolemia, and often reach standard risk thresholds many years earlier than people in the bottom of the distribution. Adding a polygenic risk score to a standard clinical risk calculator modestly improves risk discrimination in primary prevention populations, with the largest gains in younger adults whose clinical risk scores still look low.

Lipoprotein(a) and the Artery Wall

The LPA variant rs10455872 is one of the strongest single-variant predictors of premature coronary disease. Each copy of the risk allele raises lipoprotein(a) levels and the rate of coronary events, independent of LDL cholesterol. The 9p21 locus is the most replicated coronary disease gene region in the world. A meta-analysis of 16 cohorts and tens of thousands of people without prior coronary disease found that each 9p21 risk allele raises the rate of a first coronary event by roughly 19 percent.

Drug Response

SLCO1B1 controls how your liver clears certain statins. The C allele at rs4149056 raises the risk of statin-induced muscle pain about 4.5-fold per copy and 16.9-fold in CC versus TT homozygotes on simvastatin. CYP2C19 determines whether clopidogrel, a blood thinner used after stents and after some heart attacks, actually converts to its active form. The Clinical Pharmacogenetics Implementation Consortium strongly recommends that CYP2C19 intermediate and poor metabolizers receive an alternative antiplatelet drug for acute coronary syndromes or after stenting.

How to Read Your Results Together

No single line on this report decides your fate. The clinical signal lives in patterns across the categories. A few combinations are worth knowing by heart.

What to Do with Your Results

Each category has a different action threshold. The familial hypercholesterolemia variants are the most directly actionable. If you carry a pathogenic LDLR, APOB, or PCSK9 mutation, your first-degree relatives should be tested through cascade screening, your LDL target is more aggressive than the population standard, and a statin or PCSK9 inhibitor is rarely optional.

Pharmacogenetic results change which medications make sense for you before you ever take a pill. Share them with any clinician prescribing a statin or post-stent antiplatelet drug. The polygenic scores reframe your lifetime risk window. Someone in the top decile of a coronary polygenic score benefits from earlier and more aggressive prevention than someone in the bottom decile, even when today's cholesterol panel looks similar.

You only need to do the genetics once. The result stays true for life. The way you act on it should evolve as new drugs become available, polygenic risk algorithms get refined, and your own cholesterol, blood pressure, and lifestyle markers change. Reread your results every few years against the latest guidance.

When Results Can Be Misleading

Polygenic risk scores were developed mostly in people of European ancestry and predict less accurately in people of African, Asian, or Hispanic ancestry. Risk thresholds may need recalibration depending on your background. A single high-impact variant such as a pathogenic LDLR mutation does not need a polygenic score to be worth acting on. And finding no significant variants does not guarantee low cardiovascular risk. Blood pressure, smoking, diet, sedentary living, and visceral fat remain the largest movers of absolute heart risk for most people, regardless of genotype.